ELI 202Alternative Names: ELI-202 opioid
Latest Information Update: 13 Aug 2016
At a glance
- Originator Elite Pharmaceuticals
- Class Cyclopropanes; Morphinans; Opioid analgesics; Small molecules
- Mechanism of Action Opioid delta receptor antagonists; Opioid receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Pain
Most Recent Events
- 12 Aug 2016 Pivotal Bio-equivalence development is ongoing in USA (Elite Pharmaceuticals Pipeline, August 2016)